DDIT3 and diffuse large B-cell lymphoma: Inhibition of NF-κB might be insufficient to improve outcomes in addition to R-CHOP in diffuse large B-cell lymphoma, or bortezomib at the doses given might not have been sufficient to inhibit NF-κB adequately for outcomes to improve.